Navigation Links
Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
Date:11/10/2010

COLUMBIA, Md., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a late stage biotechnology drug development company that is leveraging its heat sensitive liposomal platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it has changed  the date and time to discuss third quarter 2010 results due to the Veteran's Day Holiday on November 11, 2010.  The SEC's EDGAR service will not receive, process or accept filings on November 11 because of the Veteran's Day Holiday, and Celsion is rescheduling its third quarter conference call for 3:00 p.m. ET on Monday, November 15, 2010 to enable it to allow for its quarterly report on Form 10-Q for the quarter ended September 30, 2010 and current report on Form 8-K to be filed and furnished to the SEC, respectively, and disseminated to investors in advance of the conference call in compliance with applicable SEC regulations.  To participate in the call, interested parties may dial 1-888-218-8172 (Toll free U.S./Canada) or 1-913-312-9313 (International/Toll) and use Conference ID:  4428936 to register ten minutes before the call is scheduled to begin.  The call will also be broadcast live on the internet at http://www.celsion.com.

The call will be archived for replay on Monday, November 15, 2010 at 6 p.m. ET and will remain available until Monday, November 22, 2010.  The replay can be accessed at 1-877-870-5176 (Toll Free U.S./Canada) or 1-858-384-5517 (International/Toll) using Conference ID:  4428936.  The call will also be available on the Company's website, http://www.celsion.com for 30 days after 5:00 p.m. ET on Monday, November 15, 2010.

About Celsion Corporation Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems.  Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Philips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers.  Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website:  http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

ThermoDox® is a registered trademark of Celsion Corporation.  Investor Contact:Marcy NanusThe Trout Group646.378.2927 or mnanus@troutgroup.com
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biovista Announces a Drug Repositioning Collaboration With Pfizer
2. ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010
3. Kendle Announces Third Quarter 2010 Results
4. Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors
5. Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
6. Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets
7. TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock
8. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
9. Hoya Announces Second Quarter Financial Results
10. Metamark Genetics, Inc. Announces New Chief Executive Officer
11. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Good Start ... it has eclipsed the 130 million covered lives mark ... Shield of Texas . With newly ... Company continues to enjoy strong payor acceptance based on ... clinical programs and genetic counseling, its industry-leading customer care ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL ... live events series, “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help “no-option” ...
Breaking Biology Technology:
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
Breaking Biology News(10 mins):